Kevin Johnson
Gründer bei Medicxi Ventures (Jersey) Ltd.
Ursprung des Netzwerks ersten Grades von Kevin Johnson
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Medicxi Ventures (Jersey) Ltd.
 Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.
25
| Private Company | Investment Managers | 25 |
Index Ventures (UK) LLP
9
| Subsidiary | Investment Managers | 9 |
Morphogen-IX Ltd.
 Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom.
8
| Subsidiary | Miscellaneous Commercial Services | 8 |
Levicept Ltd.
 Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom.
7
| Holding Company | Pharmaceuticals: Generic | 7 |
Inhibitaxin Ltd.
 Inhibitaxin Ltd. BiotechnologyHealth Technology Inhibitaxin Ltd. engages in research and development on biotechnology. The company was founded by Simon Lempriere Westbrook and Kevin S. Johnson in 2013 and is headquartered in Kent, the United Kingodm.
2
| Private Company | Biotechnology | 2 |
Rebalance (Cambridge) Ltd.
 Rebalance (Cambridge) Ltd. Miscellaneous Commercial ServicesCommercial Services Rebalance (Cambridge) Ltd. provides research and experimental development on biotechnology. The company was founded on December 6, 2016 and is headquartered in Hatfield, the United Kingdom.
1
| Holding Company | Miscellaneous Commercial Services | 1 |
Impact Biomedicines, Inc.
 Impact Biomedicines, Inc. Medical SpecialtiesHealth Technology Impact Biomedicines, Inc. engages in the development of cancer treatments. It engages in the development of fedratinib, a potent and selective oral molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded by John Hood, Catriona Jamieson and Raghu Saripalli in 2016 and is headquartered in San Diego, CA.
1
| Subsidiary | Medical Specialties | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Kevin Johnson
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| COMPUGEN LTD. | Biotechnology | Chairman Director/Board Member | |
| SANOFI | Pharmaceuticals: Major | Corporate Officer/Principal | |
| AEGERION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| IPSEN | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
NormOxys, Inc.
 NormOxys, Inc. Pharmaceuticals: MajorHealth Technology NormOxys, Inc. develops small-molecule therapeutics for the treatment of cancer. Its major product is OXY111A. The company was founded by Conrad J Bletzer, Jr. Claude Nicoalu, Jean-Mearie Lehn, Gay Goodman, Ruth Greferath and Roscoe Brady in 2004 and is headquartered in Brighton, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal | |
| University of Oxford | College/University | Corporate Officer/Principal Undergraduate Degree | |
| Imperial College London | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree | |
Index Ventures SA
 Index Ventures SA Investment ManagersFinance Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland. | Investment Managers | Founder Private Equity Investor Private Equity Investor Private Equity Analyst Private Equity Analyst Private Equity Investor Private Equity Analyst | |
| University of Cambridge | College/University | Graduate Degree Undergraduate Degree Doctorate Degree Graduate Degree Graduate Degree Graduate Degree | |
Andera Partners SCA
 Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Investment Managers | Corporate Officer/Principal | |
| University of California San Diego | College/University | Undergraduate Degree Corporate Officer/Principal | |
| University College London | College/University | Undergraduate Degree Doctorate Degree | |
OncoEthix SA
 OncoEthix SA Pharmaceuticals: MajorHealth Technology OncoEthix SA operates as a clinical stage biotechnology company which develops cancer drugs. Its products include OTX008, OTX015, and OTX009. The company was founded by Esteban Cvitkovic, Jeanne Kay Noel, Yves Paternot, and Patrice Herait in March 2007 and is headquartered in Luzern, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
LinguaFlex, Inc.
 LinguaFlex, Inc. Medical SpecialtiesHealth Technology LinguaFlex, Inc. develops, manufactures and distributes medical devices for the treatment of sleep apnea. It offers the LinguaFlex Tongue Retractor which is a minimally invasive device designed to be inserted into the tongue by a thin needle. The LinguaFlex Tongue Retractor is designed not to interfere with normal tongue functions such as speech and swallowing and to be removed or replaced in a doctor’s office in a short period of time without the need for anesthesia. The company was founded by Ira Sanders in 2007 and is headquartered in Pittsburgh, PA. | Medical Specialties | Director/Board Member | |
ProFibrix BV
 ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
| Université Paris Nanterre | College/University | Doctorate Degree | |
Mind-NRG SARL
 Mind-NRG SARL Medical/Nursing ServicesHealth Services Mind-NRG SARL specializes in research and development programs with focus on the treatment psychiatric and neurologic diseases. The company was founded in 2010 and is headquartered in Geneva, Switzerland. | Medical/Nursing Services | Chairman | |
Index Venture Management (US), Inc.
 Index Venture Management (US), Inc. Investment ManagersFinance Founded in 2011, Index Venture Management (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Index Venture Management SA | Investment Managers | Founder Private Equity Investor | |
Epsilon-3 Bio Ltd
 Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Other | Director/Board Member Director/Board Member | |
XO1 Ltd.
 XO1 Ltd. Medical/Nursing ServicesHealth Services XO1 Ltd. develops a novel anticoagulant drug. The firm operates as a biopharmaceutical company. The company was founded by David J. Grainger on February 28, 2013 and is headquartered in High Wycombe, the United Kingdom. | Medical/Nursing Services | Founder Founder | |
Xenikos BV
 Xenikos BV Medical SpecialtiesHealth Technology Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands. | Medical Specialties | Director/Board Member Director/Board Member | |
| Stanford Graduate School of Business | College/University | Masters Business Admin Masters Business Admin | |
| MINERVA NEUROSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Stx Pharma Ltd. | Director/Board Member Founder | ||
Phoenix Court Group Ltd
 Phoenix Court Group Ltd Investment ManagersFinance Phoenix Court Group Ltd (LocalGlobe) is a venture capital firm founded in 1999 by Robin M. Klein and Saul Charles Klein. The firm is headquartered in London, the United Kingdom. | Investment Managers | Founder Founder | |
Gadeta BV
 Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Medical Specialties | Director/Board Member Director/Board Member | |
Janpix Holdings, Inc.
 Janpix Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Janpix Holdings, Inc. engages in provision of research and experimental development on biotechnology. The company was founded by Patrick T. Gunning and Cortes Pierre and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
Z Factor Ltd.
 Z Factor Ltd. BiotechnologyHealth Technology Z Factor Ltd. operates as a drug discovery company. It identifies and develops therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was founded by James Huntington in 2015 and is headquartered in Babraham, the united Kingdom. | Biotechnology | Director/Board Member Director/Board Member Corporate Officer/Principal | |
Palladio Biosciences, Inc.
 Palladio Biosciences, Inc. BiotechnologyHealth Technology Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Galvani Bioelectronics Ltd.
 Galvani Bioelectronics Ltd. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Galvani Bioelectronics Ltd. is a pioneering research and British development company founded in 2016, dedicated to bringing bioelectronic therapies to patients. The company is based in Stevenage, UK. Galvani Bioelectronics combines GSK's therapeutics discovery and development knowledge with Verily's expertise in software and electronics for clinical applications. The company is developing therapies through implant-based direct modulation of specific neural signals to organs central in disease. These therapies are designed to be safe, precise in their therapeutic effect, and minimally invasive in their delivery through the use of small and efficient wireless electronics and keyhole surgery. Connected software will ensure that patients and physicians can effectively control and optimize the therapy. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Teatime ehf.
 Teatime ehf. Packaged SoftwareTechnology Services Teatime ehf. develops social games. The company was founded by Guðmundur Th. Bergþórsson, P. Johann Bergporsson, Thorsteinn Baldur Fridriksson and Ymir Orn Finnbogason in 2017 and is headquartered in Reykjavík, Iceland. | Packaged Software | Director/Board Member | |
UltraHuman Ltd.
 UltraHuman Ltd. Miscellaneous Commercial ServicesCommercial Services UltraHuman Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Sandwich, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
CleaVR Ltd.
 CleaVR Ltd. Miscellaneous Commercial ServicesCommercial Services CleaVR Ltd. operates under professional, scientific, and technical activities. The company was founded on July 14, 2017 and is headquartered in Macclesfield, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Critical Pressure Ltd.
 Critical Pressure Ltd. Pharmaceuticals: MajorHealth Technology Critical Pressure Ltd. engages in research and experimental development on biotechnology. The firm develops products to treat vascular dysfunction and shock. The company is headquartered in Babraham, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Human Antibody Factory Ltd.
 Human Antibody Factory Ltd. BiotechnologyHealth Technology Human Antibody Factory Ltd. provides research and experimental development on biotechnology. The company was founded by David John Grainger and is headquartered in Hatfield, the United Kingdom. | Biotechnology | Director/Board Member Founder | |
| Kaerus Bioscience Ltd. | Chairman Director/Board Member | ||
Alderaan Biotechnology SAS
 Alderaan Biotechnology SAS BiotechnologyHealth Technology Alderaan Biotechnology SAS operates as preclinical stage firm, that develops monoclonal antibodies for the treatment of cancer. The company was founded by Daniel Olive and Armand Bensussan on July 17, 2017 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
Ochre Bio Ltd.
 Ochre Bio Ltd. Pharmaceuticals: MajorHealth Technology Ochre Bio Ltd. is a biotechnology company based in Headington, UK. Ochre Bio is focused on developing RNA medicines for chronic liver diseases. The British company uses deep phenotyping, precision RNA medicine, and testing in live human donor livers to develop therapies for important liver health challenges. The company's goal is to develop therapies that increase donor liver supply and reduce cirrhosis complications. The company was founded by Quin Wills and the CEO is Jack O'Meara. | Pharmaceuticals: Major | Chairman Consultant / Advisor | |
| CENTESSA PHARMACEUTICALS PLC | Pharmaceuticals: Major | Chairman Corporate Officer/Principal Director/Board Member | |
SDS Therapeutics Ltd.
 SDS Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services SDS Therapeutics Ltd. is a British biotechnology company founded in 2020 that provides research and development services. The company is based in Cambridge, UK. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Versanis Bio, Inc.
 Versanis Bio, Inc. BiotechnologyHealth Technology Part of Eli Lilly & Co., Versanis Bio, Inc. is a clinical-stage biopharmaceutical company. The company is based in New York, NY. The company was founded by Lloyd Klickstein. Mark E. Pruzanski has been the CEO of the company since 2021. Versanis Bio was acquired by Eli Lilly & Co. on August 14, 2023 for $1,925 million. | Biotechnology | Director/Board Member | |
MyHeritage Ltd.
 MyHeritage Ltd. Internet Software/ServicesTechnology Services MyHeritage Ltd. operates a family-oriented social network service and genealogy website. The firm also provides family pages, which are personalized websites to enable families to stay in touch, celebrate birthdays, share photos, explore and preserve family history. Its solution, family tree builder, is a tool to set up a family tree and genealogy research that enables user to search for ancestors on the Internet. The company was founded by Gilad Japhet in 2003 and is headquartered in Or Yehuda, Israel. | Internet Software/Services | Director/Board Member Director/Board Member |
Statistik
International
| Vereinigtes Königreich | 22 |
| Vereinigte Staaten | 15 |
| Frankreich | 6 |
| Schweiz | 5 |
| Niederlande | 4 |
Sektoral
| Health Technology | 30 |
| Consumer Services | 8 |
| Finance | 5 |
| Commercial Services | 5 |
| Health Services | 3 |
Operativ
| Director/Board Member | 387 |
| Corporate Officer/Principal | 64 |
| Private Equity Investor | 54 |
| Independent Dir/Board Member | 53 |
| Founder | 52 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Paul Sekhri | 62 |
| Michelangelo Volpi | 57 |
| Raj Bhikhu Parekh | 50 |
| Michèle Ollier | 40 |
| Francesco de Rubertis | 36 |
| Eliot Forster | 35 |
| Robin M. Klein | 34 |
| Saul Charles Klein | 33 |
| David Grainger | 29 |
| Giuseppe Zocco | 26 |
| Moncef Slaoui | 24 |
| Sanford Zweifach | 22 |
| Aaron Kantoff | 19 |
| Robert Tansley | 18 |
| Simon Levene | 17 |
- Börse
- Insiders
- Kevin Johnson
- Unternehmensverbindungen
